Shares of leading pharmaceutical companies came under pressure on June 16 after the Union government tightened regulations governing the sale of cough syrups and other syrup based medicines. Stocks including Cipla, Sun Pharmaceutical Industries, Dr Reddys Laboratories and Glenmark Pharmaceuticals traded lower during the session, while the broader Nifty Pharma index also declined.

The regulatory change follows a notification issued by the Ministry of Health and Family Welfare that removes syrup formulations from the list of medicines eligible for relaxed sales conditions. As a result, consumers will now be required to present a valid prescription from a registered medical practitioner to purchase cough syrups and other medicinal syrups.

The move effectively ends the over the counter status previously enjoyed by several syrup based formulations. Authorities stated that the change is intended to promote responsible use of medicines, strengthen regulatory compliance and improve patient safety.

The government has been increasing scrutiny of the pharmaceutical sector following contamination related incidents involving India manufactured cough syrups in recent years. Regulators have undertaken extensive inspections of cough syrup manufacturers and introduced measures aimed at improving quality control and distribution practices.

Market participants believe the tighter sales framework could affect demand patterns for certain over the counter respiratory products, leading to investor caution toward companies with exposure to cough and cold medication segments. However, the long term impact on the broader pharmaceutical industry is expected to depend on consumer adaptation and prescription trends.